Wells Fargo’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Wells Fargo’s Portfolio KLDO Stock Details KLDO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,183	Closed	-$8K	–	8018
2022 Q1	$8K	Sell	5,183 -7,839	-60%	-$14K	﹤0.01%	6373
2021 Q4	$31K	Buy	13,022 +12,086	+1,291%	+$49.2K	﹤0.01%	6182
2021 Q3	$6K	Buy	936 +325	+53%	+$2.02K	﹤0.01%	6353
2021 Q2	$5K	Sell	611 -518	-46%	-$3.67K	﹤0.01%	6371
2021 Q1	$9K	Sell	1,129 -12,164	-92%	-$133K	﹤0.01%	6391
2020 Q4	$121K	Buy	13,293 +7	+0.1%	+$57	﹤0.01%	5286
2020 Q3	$147K	Sell	13,286 -2,211	-14%	-$15.3K	﹤0.01%	5107
2020 Q2	$115K	Buy	15,497 +4,806	+45%	+$32.2K	﹤0.01%	5165
2020 Q1	$66K	Sell	10,691 -543	-5%	-$3.54K	﹤0.01%	5249
2019 Q4	$56K	Buy	11,234 +500	+5%	+$3.18K	﹤0.01%	5482
2019 Q3	$81K	Buy	10,734 +10,695	+27,423%	+$92.8K	﹤0.01%	5406
2019 Q2	$0	Buy	+39	New	+$568	﹤0.01%	6742

Other funds holding KLDO

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Wells Fargo's KLDO Position: Q2 2022 in Review

Wells Fargo sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 5,183 shares — an estimated $8K sold.

Wells Fargo first reported a position in KLDO in Q2 2019 and held it in 12 quarters. The position peaked at $147K in Q3 2020. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

Wells Fargo reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Wells Fargo sold 5,183 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $8K.
Wells Fargo first reported a position in Kaleido Biosciences, Inc. Common Stock in Q2 2019 and held it in 12 quarters.
Wells Fargo's Kaleido Biosciences, Inc. Common Stock position peaked at $147K in Q3 2020.
3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on Wells Fargo's 13F filing for Q2 2022, filed 12 Aug 2022.